PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Thorp, HH				Thorp, H. Holden			Structural basis for strychnine activation of human bitter taste receptor TAS2R46 (Expression of Concern of Vol 377, Pg 1298, 2022)	SCIENCE			English	Expression of Concern																		Xu W., 2022, SCIENCE, V377, P6612	1	0	0	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	2022	377	6612								10.1126/science.adf8367	http://dx.doi.org/10.1126/science.adf8367			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6L1ES	36520150				2022-12-28	WOS:000887933500035
J	Ageno, W; Bertu, L; Bucherini, E; Camporese, G; Dentali, F; Iotti, M; Lessiani, G; Parisi, R; Prandoni, P; Sartori, M; Visona, A; Bigagli, E; Palareti, G				Ageno, Walter; Bertu, Lorenza; Bucherini, Eugenio; Camporese, Giuseppe; Dentali, Francesco; Iotti, Matteo; Lessiani, Gianfranco; Parisi, Roberto; Prandoni, Paolo; Sartori, Michelangelo; Visona, Adriana; Bigagli, Elisabetta; Palareti, Gualtiero		RIDTS Study Grp	Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ORAL ANTICOAGULANT-THERAPY; VENOUS THROMBOEMBOLISM; FIRST EPISODE; RECURRENCE; MANAGEMENT; OUTCOMES	OBJECTIVETo compare two different treatment durations of rivaroxaban in patients with symptomatic isolated distal deep vein thrombosis (DVT).DESIGNRandomised, double blind, placebo controlled clinical trial.SETTING28 outpatient clinics specialising in venous thromboembolism.PARTICIPANTS402 adults (a18 years) with symptomatic isolated distal DVT. INTERVENTIONS After receiving standard dose rivaroxaban for six weeks, participants were randomly assigned to receive rivaroxaban 20 mg or placebo once daily for an additional six weeks. Follow-up was for 24 months from study inclusion.MAIN OUTCOMES MEASURESThe primary efficacy outcome was recurrent venous thromboembolism during follow-up after randomisation, defined as the composite of progression of isolated distal DVT, recurrent isolated distal DVT, proximal DVT, symptomatic pulmonary embolism, or fatal pulmonary embolism. The primary safety outcome was major bleeding after randomisation until two days from the last dose of rivaroxaban or placebo. An independent committee adjudicated the outcomes.RESULTS200 adults were randomised to receive additional rivaroxaban treatment and 202 to receive placebo. Isolated distal DVT was unprovoked in 81 (40%) and 86 (43%) patients, respectively. The primary efficacy outcome occurred in 23 (11%) patients in the rivaroxaban arm and 39 (19%) in the placebo arm (relative risk 0.59, 95% confidence interval 0.36 to 0.95; P=0.03, number needed to treat 13, 95% confidence interval 7 to 126). Recurrent isolated distal DVT occurred in 16 (8%) patients in the rivaroxaban arm and 31 (15%) in the placebo arm (P=0.02). Proximal DVT or pulmonary embolism occurred in seven (3%) patients in the rivaroxaban arm and eight (4%) in the placebo arm (P=0.80). No major bleeding events occurred.CONCLUSIONSRivaroxaban administered for six additional weeks in patients with isolated distal DVT who had an uneventful six week treatment course reduces the risk of recurrent venous thromboembolism, mainly recurrent isolated distal DVT, over a two year follow-up without increasing the risk of haemorrhage.	[Ageno, Walter; Bertu, Lorenza; Dentali, Francesco] Univ Insubria, Dept Med & Surg, I-21100 Varese, Italy; [Bucherini, Eugenio] AUSL Romagna, Dept Vasc Med, Faenza, Italy; [Camporese, Giuseppe] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Unit Angiol, Padua, Italy; [Iotti, Matteo] IRCCS, AUSL, Cardiovasc Med Unit, Reggio Emilia, Italy; [Lessiani, Gianfranco] Villa Serena Hosp, Dept Internal Med, Angiol Unit, Citta S Angelo, Italy; [Parisi, Roberto] SS Giovanni & Paolo Hosp, Dept Med, Venice, Italy; [Prandoni, Paolo; Palareti, Gualtiero] Arianna Anticoagulaz Fdn, Bologna, Italy; [Sartori, Michelangelo] Univ Bologna, IRCCS Azienda Osped, Div Angiol & Blood Coagulat, Bologna, Italy; [Visona, Adriana] Azienda ULSS 2 Marca Trevigiana, Angiol Unit, Castelfranco Veneto, Italy; [Bigagli, Elisabetta] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Sect Pharmacol & Toxicol, Florence, Italy	University of Insubria; AUSL della Romagna; University of Padua; IRCCS Istituto Tumori Bari Giovanni Paolo II; University of Bologna; University of Florence	Ageno, W (corresponding author), Univ Insubria, Dept Med & Surg, I-21100 Varese, Italy.	walter.ageno@uninsubria.it						Ageno Walter, 2019, TH Open, V3, pe85, DOI 10.1055/s-0039-1683968; Ageno W, 2015, LANCET HAEMATOL, V2, pE474, DOI 10.1016/S2352-3026(15)00190-8; Astermark J, 1998, J INTERN MED, V244, P79, DOI 10.1046/j.1365-2796.1998.00318.x; Barco S, 2017, J THROMB HAEMOST, V15, P1436, DOI 10.1111/jth.13713; Donadini MP, 2017, VASC MED, V22, P518, DOI 10.1177/1358863X17720531; Ferrara F, 2006, ANGIOLOGY, V57, P418, DOI 10.1177/0003319706290745; Franco L, 2017, J THROMB HAEMOST, V15, P1142, DOI 10.1111/jth.13677; Galanaud JP, 2014, J THROMB HAEMOST, V12, P436, DOI 10.1111/jth.12512; Galanaud JP, 2009, J THROMB HAEMOST, V7, P2028, DOI 10.1111/j.1538-7836.2009.03629.x; Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301; Kuczmik W, 2021, MAYO CLIN PROC, V96, P1184, DOI 10.1016/j.mayocp.2021.01.024; Li AY, 2015, INTERN MED J, V45, P177, DOI 10.1111/imj.12664; Mazzolai L, 2022, EUR J PREV CARDIOL, V29, P1248, DOI 10.1093/eurjpc/zwab088; Palareti G, 2014, BLOOD, V123, P1802, DOI 10.1182/blood-2013-10-512616; Pinede L, 2001, CIRCULATION, V103, P2453; Prandoni P, 2015, SEMIN THROMB HEMOST, V41, P133, DOI 10.1055/s-0035-1544161; Righini M, 2016, LANCET HAEMATOL, V3, pE556, DOI 10.1016/S2352-3026(16)30131-4; Sartori M, 2014, THROMB RES, V134, P36, DOI 10.1016/j.thromres.2014.03.033; Schellong S, 2022, SEMIN THROMB HEMOST, V48, P446, DOI 10.1055/s-0041-1729169; Schellong SM, 2019, THROMB HAEMOSTASIS, V119, P1675, DOI 10.1055/s-0039-1693461; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Stevens SM, 2021, CHEST, V160, P2247, DOI 10.1016/j.chest.2021.07.056; Valerio Luca, 2019, TH Open, V3, pe58, DOI 10.1055/s-0039-1683374	24	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2022	379								e072623	10.1136/bmj-2022-072623	http://dx.doi.org/10.1136/bmj-2022-072623			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6R7CX	36520715	Green Published, hybrid			2022-12-28	WOS:000892458000008
J	Chari, A; Minnema, MC; Berdeja, JG; Oriol, A; van de Donk, NWCJ; Rodriguez-Otero, P; Askari, E; Mateos, MV; Costa, LJ; Caers, J; Verona, R; Girgis, S; Yang, SY; Goldsmith, RB; Yao, X; Pillarisetti, K; Hilder, BW; Russell, J; Goldberg, JD; Krishnan, A				Chari, Ajai; Minnema, Monique C.; Berdeja, Jesus G.; Oriol, Albert; van de Donk, Niels W. C. J.; Rodriguez-Otero, Paula; Askari, Elham; Mateos, Maria-Victoria; Costa, Luciano J.; Caers, Jo; Verona, Raluca; Girgis, Suzette; Yang, Shiyi; Goldsmith, Rachel B.; Yao, Xiang; Pillarisetti, Kodandaram; Hilder, Brandi W.; Russell, Jeffery; Goldberg, Jenna D.; Krishnan, Amrita			Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Early Access							COUPLED RECEPTOR 5D; OPEN-LABEL; DARATUMUMAB MONOTHERAPY; DOSE-ESCALATION; THERAPY; KERATINS; TARGET; MEMBER	BACKGROUND G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells. METHODS In a phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 to 180 mu g per kilogram of body weight) or subcutaneously weekly, every other week, or monthly (5 to 1600 mu g per kilogram) in patients who had heavily pretreated relapsed or refractory multiple myeloma that had progressed with established therapies (a median of six previous lines of therapy) or who could not receive these therapies without unacceptable side effects. The primary end points - the frequency and type of dose-limiting toxic effects (study part 1 only), adverse events, and laboratory abnormalities - were assessed in order to select the recommended doses for a phase 2 study. RESULTS At the data-cutoff date, 232 patients had received talquetamab (102 intravenously and 130 subcutaneously). At the two subcutaneous doses recommended for a phase 2 study (405 mu g per kilogram weekly [30 patients] and 800 mu g per kilogram every other week [44 patients]), common adverse events were cytokine release syndrome (in 77% and 80% of the patients, respectively), skin-related events (in 67% and 70%), and dysgeusia (in 63% and 57%); all but one cytokine release syndrome event were of grade 1 or 2. One dose-limiting toxic effect of grade 3 rash was reported in a patient who had received talquetamab at the 800-mu g dose level. At median follow-ups of 11.7 months (in patients who had received talquetamab at the 405-mu g dose level) and 4.2 months (in those who had received it at the 800-mu g dose level), the percentages of patients with a response were 70% (95% confidence interval [CI], 51 to 85) and 64% (95% CI, 48 to 78), respectively. The median duration of response was 10.2 months and 7.8 months, respectively. CONCLUSIONS Cytokine release syndrome, skin-related events, and dysgeusia were common with talquetamab treatment but were primarily low-grade. Talquetamab induced a substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma. (Funded by Janssen Research and Development; MonumenTAL-1 ClinicalTrials.gov number, .)	[Chari, Ajai] Mt Sinai Sch Med, New York, NY USA; [Minnema, Monique C.] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht, South Africa; [van de Donk, Niels W. C. J.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Amsterdam, Netherlands; [Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA; [Berdeja, Jesus G.] Tennessee Oncol, Nashville, TN USA; [Oriol, Albert] Hosp Germans Trias i Pujol, Inst Catala Oncol, Badalona, Spain; [Oriol, Albert] Hosp Germans Trias i Pujol, Inst Josep Carreras, Badalona, Spain; [Rodriguez-Otero, Paula] Clin Univ Navarra, Pamplona, Spain; [Askari, Elham] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain; [Mateos, Maria-Victoria] Univ Hosp Salamanca, Ctr Invest Canc, Inst Invest Biomed Salamanca, Ctr Invest Biomed Red Canc, Salamanca, Spain; [Costa, Luciano J.] Univ Alabama Birmingham, Birmingham, AL USA; [Caers, Jo] Ctr Hosp Univ Liege, Liege, Belgium; [Verona, Raluca; Girgis, Suzette; Yang, Shiyi; Goldsmith, Rachel B.; Pillarisetti, Kodandaram; Hilder, Brandi W.; Russell, Jeffery] Janssen Res & Dev, Spring House, PA USA; [Yao, Xiang] Janssen Res & Dev, La Jolla, CA USA; [Krishnan, Amrita] City Hope Comprehens Canc Ctr, Duarte, CA USA; [Goldberg, Jenna D.] Janssen Res & Dev, Raritan, NJ USA; [Chari, Ajai] Mt Sinai Sch Med, 1470 Madison Ave,3rd Fl, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; University of Amsterdam; Vrije Universiteit Amsterdam; Sarah Cannon Research Institute; Tennessee Oncology; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; Hospital Germans Trias i Pujol; Institut de Recerca Contra la Leucemia Josep Carreras (IJC); University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Alabama System; University of Alabama Birmingham; University of Liege; Johnson & Johnson; Janssen Pharmaceuticals; City of Hope; Johnson & Johnson; Janssen Pharmaceuticals; Icahn School of Medicine at Mount Sinai	Chari, A (corresponding author), Mt Sinai Sch Med, 1470 Madison Ave,3rd Fl, New York, NY 10029 USA.	ajai.chari@mountsinai.org			Janssen Research and Development	Janssen Research and Development	Supported by Janssen Research and Development.	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Atamaniuk J, 2012, EUR J CLIN INVEST, V42, P953, DOI 10.1111/j.1365-2362.2012.02679.x; Babb J, 1998, STAT MED, V17, P1103, DOI 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9; Berdeja JG, 2021, LANCET, V398, P314, DOI 10.1016/S0140-6736(21)00933-8; Chari A., 2022, 2022 AM SOC HEMATOLO; Chari A, 2019, NEW ENGL J MED, V381, P727, DOI 10.1056/NEJMoa1903455; Cohen Y, 2013, HEMATOLOGY, V18, P347, DOI 10.1179/1607845413Y.0000000079; Cornax I., 2021, 2021 SOC TOXICOLOGIC; Goldsmith R, 2021, CL LYMPH MYELOM LEUK, V21, pS91; Hutchings M, 2021, LANCET, V398, P1157, DOI 10.1016/S0140-6736(21)00889-8; Hutchings M, 2021, J CLIN ONCOL, V39, P1959, DOI 10.1200/JCO.20.03175; Inoue S, 2004, J INVEST DERMATOL, V122, P565, DOI 10.1046/j.0022-202X.2004.12628.x; Kodama T, 2019, MOL CANCER THER, V18, P1555, DOI 10.1158/1535-7163.MCT-18-1216; Kumar SK, 2017, LEUKEMIA, V31, P2443, DOI 10.1038/leu.2017.138; Kumar SK, 2012, LEUKEMIA, V26, P149, DOI 10.1038/leu.2011.196; Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46; Langbein L, 2005, INT REV CYTOL, V243, P1, DOI 10.1016/S0074-7696(05)43001-6; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lonial S, 2020, LANCET ONCOL, V21, P207, DOI 10.1016/S1470-2045(19)30788-0; Lonial S, 2016, LANCET, V387, P1551, DOI 10.1016/S0140-6736(15)01120-4; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; Mailankody S, 2021, BLOOD, V138, DOI 10.1182/blood-2021-153204; Mateos MV, 2022, LEUKEMIA, V36, P1371, DOI 10.1038/s41375-022-01531-2; Moreau P, 2022, NEW ENGL J MED, V387, P495, DOI 10.1056/NEJMoa2203478; Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850; Neuenschwander B, 2008, STAT MED, V27, P2420, DOI 10.1002/sim.3230; Palumbo A, 2009, BLOOD REV, V23, P87, DOI 10.1016/j.blre.2008.07.003; Pardridge WM, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14060535; Pillarisetti K, 2020, BLOOD, V135, P1232, DOI 10.1182/blood.2019003342; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Schweizer J, 2007, EXP CELL RES, V313, P2010, DOI 10.1016/j.yexcr.2007.02.032; Smith EL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7746; Thibaut S, 2003, EXP DERMATOL, V12, P160, DOI 10.1034/j.1600-0625.2003.00046.x; Verkleij CPM, 2021, BLOOD ADV, V5, P2196, DOI 10.1182/bloodadvances.2020003805	35	0	0	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMoa2204591	http://dx.doi.org/10.1056/NEJMoa2204591		DEC 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6Y0AO	36507686				2022-12-28	WOS:000896767900001
J	Shin, H; Schneeweiss, S; Glynn, RJ; Patorno, E				Shin, Hojin; Schneeweiss, Sebastian; Glynn, Robert J.; Patorno, Elisabetta			Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							ADMINISTRATIVE DATA; MORTALITY; SAFETY; MELLITUS; COMPLICATIONS; PREVALENCE; MEDICATION; FRACTURES; VALIDITY; CODES	Background: Evidence on the risk for cardiovascular events associated with use of first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared with metformin is limited. Objective: To assess cardiovascular outcomes among adults with type 2 diabetes (T2D) who initiated first-line treatment with SGLT-2i versus metformin. Design: Population-based cohort study. Setting: Claims data from 2 large U.S. commercial and Medicare databases (April 2013 to March 2020). Participants: Patients with T2D aged 18 years and older (>65 years in Medicare) initiating treatment with SGLT-2i or metformin during April 2013 to March 2020, without any use of antidiabetic medications before cohort entry, were identified. After 1:2 propensity score matching in each database, pooled hazard ratios (HRs) and 95% CIs were reported. Intervention: First-line SGLT-2i (canagliflozin, empagliflozin, or dapagliflozin) or metformin. Measurements: Primary outcomes were a composite of hospitalization for myocardial infarction (MI), hospitalization for ischemic or hemorrhagic stroke or all-cause mortality (MI/stroke/mortality), and a composite of hospitalization for heart failure (HHF) or all-cause mortality (HHF/mortality). Safety outcomes including genital infections were assessed. Results: Among 8613 first-line SGLT-2i initiators matched to 17 226 metformin initiators, SGLT-2i initiators had a similar risk for MI/stroke/mortality (HR, 0.96; 95% CI, 0.77 to 1.19) and a lower risk for HHF/mortality (HR, 0.80; CI, 0.66 to 0.97) during a mean follow-up of 12 months. Initiators receiving SGLT-2i showed a lower risk for HHF (HR, 0.78; CI, 0.63 to 0.97), a numerically lower risk for MI (HR, 0.70; CI, 0.48 to 1.00), and similar risk for stroke, mortality, and MI/stroke/HHF/mortality compared with metformin. Initiators receiving SGLT-2i had a higher risk for genital infections (HR, 2.19; CI, 1.91 to 2.51) and otherwise similar safety as those receiving metformin. Limitation: Treatment selection was not randomized. Conclusion: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.	[Shin, Hojin; Schneeweiss, Sebastian; Glynn, Robert J.; Patorno, Elisabetta] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St Suite 3030, Boston, MA 02120 USA; [Shin, Hojin; Schneeweiss, Sebastian; Glynn, Robert J.; Patorno, Elisabetta] Harvard Med Sch, 1620 Tremont St Suite 3030, Boston, MA 02120 USA; [Schneeweiss, Sebastian] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Shin, H (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St Suite 3030, Boston, MA 02120 USA.; Shin, H (corresponding author), Harvard Med Sch, 1620 Tremont St Suite 3030, Boston, MA 02120 USA.	hos739@mail.harvard.edu		Shin, HoJin/0000-0002-2032-6134; Schneeweiss, Sebastian/0000-0003-2575-467X; Patorno, Elisabetta/0000-0002-8809-9898	Brigham and Women's Hospital and Harvard Medical School	Brigham and Women's Hospital and Harvard Medical School	Brigham and Women's Hospital and Harvard Medical School.	Aetion, SOFTW REALW DAT AN; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2010, AM J EPIDEMIOL, V172, P1092, DOI 10.1093/aje/kwq224; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Bansal V, 2006, POSTGRAD MED J, V82, P95, DOI 10.1136/pgmj.2005.036137; Barr ELM, 2007, CIRCULATION, V116, P151, DOI 10.1161/CIRCULATIONAHA.106.685628; Belatti DA, 2013, FOOT ANKLE INT, V34, P923, DOI 10.1177/1071100713475357; Bobo WV, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-157; Chen TH, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01169-3; Chen YQ, 2015, J DIABETES COMPLICAT, V29, P1228, DOI 10.1016/j.jdiacomp.2015.07.005; Cosentino F., 2020, EUR HEART J, V41, P255, DOI [10.1093/eurheartj/ehz486, DOI 10.1093/eurheartj/ehz486]; COX DR, 1972, J R STAT SOC B, V34, P187; Dave CV, 2019, ANN INTERN MED, V171, P248, DOI 10.7326/M18-3136; Dave CV, 2019, DIABETES OBES METAB, V21, P434, DOI 10.1111/dom.13531; Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033; DeSantis A., SODIUM GLUCOSE COTRA; Fralick M, 2021, DIABETES OBES METAB, V23, P2320, DOI 10.1111/dom.14474; Franklin JM, 2021, CIRCULATION, V143, P1002, DOI 10.1161/CIRCULATIONAHA.120.051718; Gilbert RE, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0812-6; Ginde Adit A, 2008, BMC Endocr Disord, V8, P4, DOI 10.1186/1472-6823-8-4; Giorgino F, 2020, DIABETES OBES METAB, V22, P1481, DOI 10.1111/dom.14055; Glynn RJ, 2001, EPIDEMIOLOGY, V12, P682, DOI 10.1097/00001648-200111000-00017; Groenwold RHH, 2012, CAN MED ASSOC J, V184, P1265, DOI 10.1503/cmaj.110977; Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254; Hudson M, 2013, J CLIN EPIDEMIOL, V66, P278, DOI 10.1016/j.jclinepi.2012.10.004; IBM Watson Health, IBM MARKETSCAN RES D; Khokhar B, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009952; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Lin DSH, 2021, DIABETOLOGIA, V64, P2676, DOI 10.1007/s00125-021-05529-w; Lin E, PREPRINT, DOI [10.48550/arXiv.2002.04211, DOI 10.48550/ARXIV.2002.04211]; McGuire DK, 2021, JAMA CARDIOL, V6, P148, DOI 10.1001/jamacardio.2020.4511; Miller DR, 2004, DIABETES CARE, V27, pB10, DOI 10.2337/diacare.27.suppl_2.B10; Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925; Nyirjesy P, 2013, POSTGRAD MED, V125, DOI 10.3810/pgm.2013.05.2650; Patorno E, 2021, DIABETES CARE, V44, P826, DOI 10.2337/dc20-1464; Patorno E, 2019, DIABETES CARE, V42, P2204, DOI 10.2337/dc19-0069; Patorno E, 2018, DIABETES OBES METAB, V20, P974, DOI 10.1111/dom.13184; Patorno E, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k119; Patorno E, 2015, PHARMACOEPIDEM DR S, V24, P565; Raebel MA, 2013, ANN PHARMACOTHER, V47, P1280, DOI 10.1177/1060028013503624; RAY WA, 1992, J CLIN EPIDEMIOL, V45, P703, DOI 10.1016/0895-4356(92)90047-Q; Research Data Assistance Center (ResDAC), MAST BEN SUMM FIL MB; Rothman KJ, EPISHEET SPREADSHEET; RStudio Team, RSTUDIO INT DEV ENV; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Saczynski JS, 2012, PHARMACOEPIDEM DR S, V21, P129, DOI 10.1002/pds.2313; Scheen AJ, 2018, CIRC RES, V122, P1439, DOI 10.1161/CIRCRESAHA.117.311588; Schelleman H, 2010, CLIN PHARMACOL THER, V88, P214, DOI 10.1038/clpt.2010.74; Schneeweiss S, 2016, CLIN PHARMACOL THER, V99, P262, DOI 10.1002/cpt.316; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Schneeweiss S, 2010, PHARMACOEPIDEM DR S, V19, P858, DOI 10.1002/pds.1926; Shin H, 2022, PHARMACOEPIDEM DR S, V31, P566, DOI 10.1002/pds.5406; Shin H, 2021, DIABETES CARE, V44, P1774, DOI 10.2337/dc20-2926; Social Security Administration, REQ SSAS DEATH INF; Suissa S, 2018, DIABETES CARE, V41, P219, DOI 10.2337/dc17-1059; Sundstrom J, 2021, J DIABETES COMPLICAT, V35, DOI 10.1016/j.jdiacomp.2021.107996; Tchetgen ET, 2014, AM J EPIDEMIOL, V179, P633, DOI 10.1093/aje/kwt303; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; U.S. Food and Drug Administration, SUPPL APPR LETT EMP; U.S. Food & Drug Administration, FRAM FDAS REAL WORLD; US Food and Drug Administration, 2008, GUID IND DIAB MELL E; Verbrugge Frederik H, 2017, Curr Heart Fail Rep, V14, P275, DOI 10.1007/s11897-017-0340-1; Wahl PM, 2010, PHARMACOEPIDEM DR S, V19, P596, DOI 10.1002/pds.1924; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073; Wang SV, 2016, CLIN PHARMACOL THER, V99, P325, DOI 10.1002/cpt.329; Wang SV, 2018, AM J EPIDEMIOL, V187, P1799, DOI 10.1093/aje/kwy049; Wang SV, 2014, EPIDEMIOLOGY, V25, P772, DOI 10.1097/EDE.0000000000000148; Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389; Xie Y, 2021, JAMA INTERN MED, V181, P1043, DOI 10.1001/jamainternmed.2021.2488; Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827	74	2	2	5	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2022	175	7					927	+		10.7326/M21-4012	http://dx.doi.org/10.7326/M21-4012		MAY 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3F4ZO	35605236				2022-12-28	WOS:000803044900001
J	Mahase, E				Mahase, Elisabeth			Meningitis vaccine could protect against gonorrhoea, studies find	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Abara WE, 2022, LANCET INFECT DIS, V22, P1021, DOI 10.1016/S1473-3099(21)00812-4; Wang B, 2022, LANCET INFECT DIS, V22, P1011, DOI 10.1016/S1473-3099(21)00754-4; Whittles LK, 2022, LANCET INFECT DIS, V22, P1030, DOI 10.1016/S1473-3099(21)00744-1	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2022	377								o997	10.1136/bmj.o997	http://dx.doi.org/10.1136/bmj.o997			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1H2DR	35440432				2022-12-28	WOS:000796356300005
